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Abstract 
The parallel synthesis of a 26-membered-library of aromatic/aliphatic-(thio)urea-linked 
pyrrolizidines followed by in situ biological evaluation towards -galactosidases has been 
carried out. The combination of the (thio)urea-forming  click reaction and the in situ screening 
is pioneer in the search for glycosidase inhibitors and has allowed the discovery of a potent 
coffee bean α-galactosidase inhibitor (IC50 = 0.37 μM, Ki = 0.12 µM) that has also showed 
inhibition against human lysosomal α-galactosidase (α-Gal A, IC50 = 5.3 μM, Ki = 4.2 µM). 
Keywords: iminosugars; glycosidase inhibitors; pyrrolizidines; click chemistry; in situ 
screening; α-galactosidases. 
Introduction 
Glycosidases are enzymes that catalyze the hydrolysis of the glycosidic bond of 
oligosaccharides and glycoconjugates. They are involved in a wide range of biological 
processes from metabolism to cell-cell and cell-virus recognition.1 The inhibition of these 
enzymes is therefore an important target in order to find new therapeutic agents against diseases 
such as diabetes, viral infections, lysosomal storage disorders and tumor metastasis.2 
Iminosugars, carbohydrate mimics with the endocyclic oxygen replaced by a nitrogen atom, 
constitute the most important family of glycosidase inhibitors due to their ability of mimicking 
the corresponding oxocarbenium ion or the transition state of the enzyme-catalyzed O-glycoside 
hydrolysis, after protonation at physiological pH.3 Although many natural iminosugars, 
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including polyhydroxylated piperidines, pyrrolidines, indolizidines, pyrrolizidines and 
nortropanes (Figure 1a), show potent glycosidase inhibition properties, they often lack of 
selectivity, which, together with their low membrane permeability, limits their use as 
pharmacological agents. Thus, numerous efforts have been devoted to the synthesis of more 
potent and selective inhibitors.4 Several piperidine derived iminosugars such as Glyset® (N-(2-
hydroxyethyl)-1-deoxynojirimycin), Zavesca® (N-butyl-1-deoxynojirimycin) or more recently 
Galafold® (1-deoxygalactonojirimycin) (Figure 1b) are commercialized as drugs against type II 
diabetes, Gaucher and Fabry diseases, respectively.5  
 
Figure 1. a) Families of iminosugars; b) Current drugs from iminosugars; c) Examples of bioactive 
natural pyrrolizidines. 
Pyrrolizidine iminosugars such as casuarine, australine and hyacinthacines (Figure 1c) are good 
inhibitors of several glucosidases but they often present a limited selectivity, possibly due to the 
high conformational flexibility of the bicyclic system.6 With the aim of improving the 
glycosidase inhibition potency and specificity of these inhibitors, most of the structural 
modifications made have involved changes in the configuration and number of hydroxyl groups 
of the pyrrolizidine ring.7,8 Few examples of other types of modifications in the pyrrolizidine 
ring (fluorination, C-alkylation/arylation and amidation of amino-derivatives) have been 
described.9 Recently, the first naturally occurring polyhydroxylated pyrrolizidine containing an 
acetamidomethyl group (pochonicine) has showed potent inhibition against -N-
acetylglucosaminidases (GlcNAcases), being inactive towards other glycosidases. The synthesis 
of several stereoisomers of pochonicine has been also reported.10   
Although many of these polyhydroxylated pyrrolizidines present interesting inhibition 
properties, none of them has been yet approved as a drug. Most polyhydroxylated pyrrolizidines 
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reported in the bibliography are tetra- or penta-hydroxylated and include an hydroxymethyl 
substituent on the bicyclic core (Figure 1c). Recent applications of glycosidase inhibitors as 
chaperones for lysosomal storage diseases (LSDs) require the inhibitors to cross the cell 
membranes (cell and ER permeability).5 We and others have demonstrated that the 
incorporation of (hetero)aromatic moieties into monocyclic iminosugars (syn-3,4-
dihydroxylated pyrrolidines) affords glycosidase inhibitors with increased potency and 
selectivity, which may be due to additional non-glycone interactions with the enzyme.11 
Therefore, the attaching of different aliphatic/aromatic moieties into a pyrrolizidine skeleton 
with a lower degree of hydroxylation seems to be an attractive approach to improve the 
selectivity and potency of these compounds, increasing, at the same time, the lipophilic 
character necessary to cross the cell membranes. 
Click chemistry12 represents an efficient synthetic methodology that connects two readily 
available building blocks. This approach is currently used in drug discovery13 by providing a 
mean for the fast preparation of hybrid molecules that facilitate lead optimization by structure-
activity relationship (SAR) through the generation of libraries of derivatives.  In particular, the 
use of the copper catalyzed azide alkyne cycloaddition (CuAAC) as click reaction has been 
broadly exploited for the generation of bioactive molecules in medicinal chemistry.14 This 
reaction has been successfully used in the preparation of monomeric and multimeric 
iminosugar-triazole derivatives in order to improve the glycosidase inhibitory properties of the 
adequate iminosugar lead.15 In this sense, we have recently applied a combinatorial strategy 
based on the generation of libraries of pyrrolidine-triazole derivatives via CuAAC that, in 
combination with their in situ biological screening, has allowed us the rapid and efficient 
discovery of potent glycosidase inhibitors.11a,16 Part of the success of this strategy relies on the 
choice of the key reaction for the preparation of the library, as high-yielding reactions that do 
not generate by-products that could interfere in the further in situ biological analysis are needed. 
Although CuAAC largely fulfills these requirements,17 the toxicity of copper catalyst may be a 
limiting factor for its use in the preparation of compounds for pharmaceutical applications,18 as 
in many cases copper (I) can coordinate with the compound,19 being difficult to remove in the 
purification process. Although other click reactions have been developed and employed in 
medicinal chemistry,20 their application for the generation and in situ biological screening in the 
field of glycosidase inhibition is limited.  
We report herein the synthesis and biological evaluation of a family of aromatic-linked epimeric 
pyrrolizidines obtained by different click reactions (urea, thiourea and triazole formation), in 
order to compare their biological activity. The most potent inhibitor will be chosen as model 
compound for the generation of a combinatorial library that will be in situ screened towards 
commercial glycosidases (Figure 2).  
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Figure 2. General strategy developed in this work. 
Results and discussion 
Synthesis and selection of the lead compound for the generation of the library. 
Our goal in this work was the synthesis of several hydroxylated pyrrolizidine derivatives in 
order to identify a suitable lead compound for the search of new selective glycosidase inhibitors. 
Thus, we performed a preliminary study of the glycosidase inhibition of several pyrrolizidine 
derivatives bearing an aromatic moiety through different linkers (Scheme 1).  The idea was to 
prepare these compounds starting from aminopyrrolizidines 1, and study the effect of the 
configuration and type of substitution at C-6 on the inhibition of glycosidases by derivatives 2-
5. Two types of click reactions were chosen for this purpose, (a) the Cu(I)-catalyzed azide 
alkyne cycloaddition (CuAAC) between an azido-pyrrolizidine and an alkyne and (b) the 
(thio)urea-forming reaction between an amino-pyrrolizidine and an iso(thio)cyanate. 
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Scheme 1.Aromatic-(thio)urea/triazole-linked pyrrolizidines for preliminar biological exploration. 
The synthesis of amino-pyrrolizidines 1 started from alcohol 6,21 previously described by 
Wightman and co-workers. Swern oxidation of 6 followed by reductive amination with 
ammonia in the presence of titanium tetraisopropoxide furnished amines 1 as an inseparable 
diastereoisomeric mixture. Subsequent reaction between amino-pyrrolizidines 1 and 3,5-
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bis(trifluoromethyl)phenylisothiocyanate gave the diastereomeric thioureas 8a and 9a which 
could be separated by column chromatography and were further deprotected to give 2a and 3a 
(Scheme 2). The configuration at C-6 in diastereoisomers 2a and 3a was assigned by X-ray 
crystal structure of the precursors 8a and 9a (Figure 3).22 Ureas 2A and 3A were similarly 
obtained after reaction of 1 with 3,5-bis(trifluoromethyl)phenylisocyanate followed by acidic 
deprotection. The C6-(R)-configuration of diastereoisomer 2A was assigned by NOESY 
spectrum which showed a conclusive NOE between H-6 and H-1 (Figure 4). Acidic 
deprotection of alcohol 6 was also carried out to give known trihydroxylated pyrrolizidine 10.21 
 
Scheme 2. Synthesis of aromatic-(thio)urea-linked pyrrolizidines. 
               
Figure 3. ORTEP diagrams for 8a (left) and 9a.HCl (right) with ellipsoids set at 50% probability (most 
of the hydrogen atoms were omitted for clarity). 
Triazoles 11 and 12 were obtained from amines 1 in a sequential one-pot diazo transfer reaction 
followed by intermolecular CuAAC (Scheme 3).23 Subsequent acidic deprotection afforded 
derivatives 4 and 5. In the case of 4, a NOE between H-6 and H-1 confirmed the R configuration 
for C(6) (Figure 4). 
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Scheme 3. Synthesis of aromatic-triazole-linked pyrrolizidines. 
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Figure 4. Confirmation of the C(6) configuration in 2A and 4  by NOE experiments. 
The biological evaluation of aromatic-linked pyrrolizidines 2a, 2A, 3a, 3A, 4, 5 and alcohol 910 
towards eleven commercial glycosidases was carried out (see Table 1). Thiourea 3a only 
showed a strong inhibition towards α-galactosidase from coffee beans (IC50 = 3.1 μM) and a 
moderate inhibition against α-mannosidases from Jack bean (IC50 = 38 μM). It is noteworthy 
that the corresponding urea analogue 3A proved to be a more selective α-galactosidase inhibitor 
as it lost α-mannosidase inhibition. Triazole derivative 4 showed a moderate inhibition towards 
α-L-fucosidase (IC50 = 46 μM) and α-galactosidase (IC50 = 53 μM), and a high inhibition 
towards α-mannosidase (IC50 = 9.1 μM) while its epimer 5 proved to be a moderate but more 
selective inhibitor of α-galactosidase (IC50 = 57 μM). Urea and thiourea pyrrolizidines 2a and 
2A only showed a weak inhibition towards some of the enzymes, which indicates the 
importance of the configuration at C6 on the inhibition properties of this type of compounds. 
Besides, the inhibition data for alcohol 10 in comparison with those of 3a and 3A, which have 
the same configuration at C6, showed that the incorporation of an aromatic moiety through an 
urea or thiourea bridge considerably improves the enzymatic inhibition.  After this preliminar 
screening, compounds 3a and 3A appeared to be interesting leads for the search of new α-
galactosidase inhibitors. It is remarkable the difference in the inhibition properties of compound 
3A and our previously described monocycle analogue 13 (see Table 1),  despite the slight 
differences on their aromatic substituents.16a While phenyl-thiourea-linked pyrrolidine 13 is a 
moderate-to-weak β-glucosidase inhibitor, the rigid analogue (pyrrolizidine 3A) is a potent α-
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galactosidase inhibitor, showing the influence of the conformation in the inhibition selectivity 
profile . 
 
Table 1. Inhibitory activities of compounds 2-5, 10 and 13 towards glycosidases. % Inhibition at 100 µM 
of inhibitor and IC50 (in parenthesis). Optimal pH for each enzyme, 37 ºC.a,b 
 
Compound  α-L-fucosidase 
(bovine kidney) 
α-galactosidase 
(coffee beans) 
α-mannosidase 
(Jack beans) 
β-glucosidase 
(almonds) 
 
2a, X = S 
 
2A, X = O 
NI 
 
23% 
NI 
 
24% 
NI 
 
18% 
NI 
 
NI 
 
3a, X = S 
 
3A, X = O 
NI 
 
NI 
88% 
(3.1 µM) 
 
82% 
(9.2 µM) 
71% 
(38 µM) 
 
26% 
NI 
 
NI 
 
  
65% 
 (46 µM) 
 
56%  
(53 µM) 
 
86%  
(9.1 µM) NI 
 
 
19% 58% 
(57 µM) 
25% NI 
 
 
NI NI NI NI 
 
 
NId NId NId 76%c,d 
a NI = no inhibition detected. 
b No inhibition was detected towards these other eight enzymes: β-galactosidases (Aspergillus oryzae and Escherichia 
coli), α-glucosidases (yeast and rice), β-N-acetylglucosaminidase (Jack bean), amyloglucosidase (Aspergillus niger), 
β-mannosidase (snail). 
c % Inhibition at 1000 µM of inhibitor. 
d Inhibition data reported in reference 16a. 
 
Generation of a library of aromatic-(thio)urea-linked pyrrolizidines and in situ screening as 
α-galactosidase inhibitors 
The (thio)urea-forming click reaction between the unprotected (6R)-6-amino-pyrrolizidine 16 
and a set of iso(thio)cyanates followed by in situ biological evaluation seemed to be ideal for 
the rapid discovery of potent glycosidase inhibitors. The preparation of diastereomerically pure 
16 was achieved after Boc protection of amino-pyrrolizidines 1 followed by chromatographic 
separation of diastereoisomers 14 and 15 and subsequent acidic deprotection of 14 (Scheme 4).  
Parallel (thio)urea-forming reactions between amino-pyrrolizidine 16 (1.2 equiv.) and 
isothiocyanates a–q (1.0 equiv.) and isocyanates A-I (1.0 equiv.) were carried out using DMSO 
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as solvent (Scheme 4). TLC and ESI-MS analysis of the mixtures showed after 6 h at r.t 
complete conversion and the presence of the desired compounds (See Supporting information 
for Electrospray mass spectra). After water dilution, the in situ screening of the resulting crude 
pyrrolizidine-(thio)ureas towards α-galactosidase (coffee beans) was carried out in a 96-well 
microtiter plate containing 5.0 µM of the potential inhibitor in each well, assuming complete 
reactions (see Experimental section for details).  
 
 
Scheme 4. Parallel (thio)urea-forming click reactions followed by in situ screening. 
From the preliminary analysis of the (thio)urea-pyrrolizidine library (Figure 5) it is clear that the 
incorporation of an aromatic/aliphatic moiety to the pyrrolizidine skeleton significantly 
enhances the enzymatic inhibition compared to amino-pyrrolizidine 16. Besides, the thiourea 
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derivatives (3a-q) resulted to be better inhibitors than the corresponding urea counterparts (3A-
I). In particular, thiourea 3i (93% inhibition at 5.0 µM) stood out among all the derivatives 
evaluated. In order to carry out a more accurate inhibition study, compound 3i was prepared in 
higher scale and purified by column chromatography (Scheme 4). This compound was 
evaluated towards a collection of commercial glycosidases. At 0.1 mM concentration, 3i only 
showed significant inhibition towards α-galactosidase from coffee beans, being the IC50 = 0.37 
M and Ki = 0.12 M (mixed-type of inhibition), and moderate inhibition towards Jack bean α-
mannosidase (IC50 = 79 μM).  
Figure 5. % Inhibition of -galactosidase from coffee beans at 5.0 µM of pyrrolizidine-thioureas (in 
blue) and pyrrolizidine-ureas (in red) (pH 6, 37 ºC). 
Coffee beans α-galactosidase presents 58% homology with human lysosomal α-galactosidase,24 
the enzyme involved in Fabry disease,25 both belonging to the CAZy family GH27. The X-ray 
structure of human α-Gal A is known since 2004.26 The structure is a homodimer with each 
monomer composed with two domains. Domain 1, which contains an active site, has a higher 
frequency of point mutations leading to Fabry disease. The previously reported crystal structure 
of human α-galactosidase in complex with a 1-deoxygalactonojirimycin-arylthiourea  shows the 
ability of the aryl-NH thiourea proton to interact via hydrogen bond with the catalytic Asp-231 
of α-Gal A.27 Thus, 3i was also evaluated against this human enzyme, showing an IC50 of 5.3 
M (Ki = 4.2 M, mixed-type of inhibition). Compound 3a, which is weaker inhibitor than 3i 
towards the plant enzyme, was also evaluated towards the human enzyme, showing also weaker 
inhibition against the latter (IC50 = 68 M). These data show a correspondence between the 
0
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behaviour of our inhibitors against both enzymes, which makes our approach useful for the 
preliminary selection of compounds as potential human lysosomal α-galactosidase inhibitors. 
Conclusions 
We have prepared a 26-membered-library of aromatic(aliphatic)-(thio)urea-linked pyrrolizidines 
that after in situ screening has allowed the rapid identification of a potent and selective coffee 
bean α-galactosidase inhibitor (compound 3i), that also showed inhibition against human 
lysosomal α-galactosidase. To the best of our knowledge this is the first pyrrolizidine-scaffolded 
iminosugar showing α-galactosidase inhibition in the nanomolar range. Moreover the high 
lipophilicity of 3i, with only two hydroxyl groups and an aromatic substituent, makes this 
inhibitor of interest for applications requiring the cross of cell membranes (i.e. chaperones for 
Fabry disease). The combination of the well-known metal-free (thio)urea-forming click reaction 
and in situ biological screening has been successfully used for the first time in the search for 
new glycosidase inhibitors and could be extended to the discovery of many other biologically 
relevant molecules.  
Experimental part 
General methods. 
Optical rotations were measured in a 1.0 cm or 1.0 dm tube with a Jasco P-2000 
spectropolarimeter. Infrared spectra were recorded with a Jasco FTIR-410 spectrophotometer. 
1H and 13C NMR spectra were recorded with a Bruker AMX300, AV300 for solutions in CDCl3 
and CD3OD. δ are given in ppm and J in Hz. J are assigned and not repeated. All the 
assignments were confirmed by COSY and HSQC experiments. High resolution mass spectra 
were recorded on a Q-Exactive spectrometer. NMR and mass spectra were registered in CITIUS 
(University of Seville). TLC was performed on silica gel 60 F254 (Merck), with detection by UV 
light charring with p-anisaldehyde, vanillin, ninhydrin or with Pancaldi reagent [(NH4)6MoO4, 
Ce(SO4)2, H2SO4, H2O]. Silica gel 60 (Merck, 40-60 and 63-200 μm) was used for preparative 
chromatography. 
Generation of the combinatorial library followed by in situ biological screening. 
To 300 μL of a solution of pyrrolizidine 16 (28 mM in DMSO) in an eppendorf, 100 μL of a 
solution of the corresponding iso(thio)cyanate (a-q, A-I)  (70 mM in DMSO) was added. All the 
eppendorfs containing the resulting mixtures were shaken at room temperature for 6 h and 
monitored for completion by TLC (AcOEt:Cy, 1:1) and ESI-MS (see Supporting information 
for mass spectra analysis). Then, the reaction mixtures were diluted with water to the desired 
concentration and placed in a 96-well microtiter plate in order to perform the enzymatic assays 
against coffee bean α-galactosidase. The final concentration of (thio)ureas on each well was 5.0 
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μM (assuming quantitative conversion in the click reaction). The inhibition measures were 
performed according the general procedure described bellow. 
Inhibition studies with commercial enzymes 
The % of inhibition towards the corresponding glycosidase was determined in the presence of 
0.1 mM (5.0 μM for crude library 3a-q,A-I) of the inhibitor on the well. Each enzymatic assay 
(final volume 0.12 mL) contains 0.01-0.5 units/mL of the enzyme and 4.2 mM aqueous solution 
of the appropriate p-nitrophenyl glycopyranoside (substrate) buffered to the optimal pH of the 
enzyme. Enzyme and inhibitor were pre-incubated for 5 min at rt, and the reaction started by 
addition of the substrate. After 20 min of incubation at 37 °C, the reaction was stopped by 
addition of 0.1 mL of sodium borate solution (pH 9.8). The p-nitrophenolate formed was 
measured by visible absorption spectroscopy at 405 nm. Under these conditions, the p-
nitrophenolate released led to optical densities linear with both reaction time and concentration 
of the enzyme. The IC50 value (concentration of inhibitor required for 50% inhibition of enzyme 
activity) was determined from plots of % inhibition versus different inhibitor concentrations. 
The mode of inhibition for 3i was determined by the Lineweaver-Burk double-reciprocal plots 
(1/V versus 1/[S] at different inhibitor concentrations) to give the apparent Km (the Km in the 
presence of the inhibitor). The graph was performed using six substrate concentrations around 
the Km of the enzyme for each inhibitor concentration. Four different inhibitor concentrations, 
bracketing the IC50 value, were used for each determination. From the analysis of this graph, a 
secondary plot was generated from the representation of the slope (Kmapparent/Vmax) versus 
[inhibitor]; Ki was calculated from the negative value of the x-intercept of this plot. In case of 
mixed-type of inhibition, another secondary plot was generated from the original Lineweaver-
Burk graph, plotting the Y-intercepts (1/Vmaxapparent) versus [inhibitor]; K’i was calculated 
from the negative value of the X-intercept of this plot. 
 
Synthesis and characterization of the new compounds. 
(1S,2R,7aS)-1,2-O-Isopropylidendioxy-pyrrolizidin-6-one (7): Anhydrous DMSO (1.9 mL, 
26 mmol) was added dropwise to a stirred solution of oxalyl chloride (1.1 mL, 13 mmol) in 
anhydrous CH2Cl2 (15 mL) at -65 °C. The mixture was stirred at –65 °C for 15 min and then a 
solution of alcohol 621 (1.28 g, 6.44 mmol) in anhydrous CH2Cl2 (20 mL) was added. The 
mixture was stirred for 5 h at -65 °C and then Et3N (4.5 mL, 32 mmol) was added. The mixture 
was allowed to reach r.t. and then evaporated. Chromatographic purification on silica gel 
(diethyl ether:acetone, 3:1) afforded 7 (1.2 g, 6.1 mmol, 95%) as a  pale orange solid.  27Dα -
215.6 (c 0.70, CH2Cl2). IR νmax 2985, 2938, 1739 (C=O), 1151, 864, 621 cm-1. 1H-NMR (300 
MHz, CDCl3, δ ppm, J Hz) δ 4.86 (dd, 1H, J2,1 = 6.0, J2,3’= 4.7, H-2), 4.68 (d, 1H, H-1), 3.86 
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(dd, 1H, J7a,7’ = 11.1, J7a,7 = 7.5, H-7a), 3.78-3.31 (m, 2H, H-3, H-5), 3.12 (d, 1H, J5’,5 = 18.9, H-
5’), 2.67 (dd, 1H, J3’,3 = 11.7, H-3’), 2.39 (dd, 1H, J7,7’ = 18.6, H-7), 2.03 (ddd, 1H, J7’,5’ = 0.9, 
H-7’), 1.57, 1.34 (2s, 3H each, -C(CH3)2). 13C-NMR (75.4 MHz, CDCl3, δ ppm) δ 217.7 (C=O), 
111.9 (-C(CH3)2), 83.9 (C-1), 80.7 (C-2), 68.0 (C-7a), 61.5 (C-3), 59.2   (C-5), 37.2 (C-7), 26.5 
(-C(CH3)2), 24.7 (-C(CH3)2).  HRMS (ESI-ORBITRAP) m/z: [M+H]+ calcd. for C10H16NO3 
198.1125; Found 198.1120.(1S,2R,6R,7aS)- and (1S,2R,6S,7aS)-6-Amino-1,2-O-
isopropylidendioxy-pyrrolizidine (1):  
A solution of 7 (239 mg, 1.21 mmol) and Ti(OiPr)4 (0.71 mL, 2.4 mmol) in abs. EtOH (8 mL) 
was saturated with ammonia. After 6 h at r.t., NaBH4 (72 mg, 1.8 mmol) was added and the 
mixture was stirred for 4 h. Then, 2 M NH4OH (6 mL) was added and the mixture was filtered 
through celite and washed with EtOH and AcOEt. The filtrate was evaporated and the residue 
purified through chromatography column on silica gel (CH2Cl2:MeOH:NH4OH, 
7:1:0.05→5:1:0.05) to afford 1 (199 mg, 1.01 mmol, 83%) as a mixture of diastereoisomers that 
was directly used for derivatization. 
N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-[(1S,2R,6R,7aS)-1,2-O-isopropylidendioxy-
pyrrolizidin-6-yl]thiourea (8a) and N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-
[(1S,2R,6S,7aS)-1,2-O-isopropylidendioxy-pyrrolizidin-6-yl]thiourea (9a): To a solution of 
diastereomeric amines 1 (196 mg, 0.99 mmol) in CH2Cl2 (10 mL), 3,5-
bis(trifluoromethyl)phenylisothiocyanate (0.46 mL, 2.5 mmol) was added and the mixture 
stirred for 2.5 h at r.t. After evaporation to dryness, the crude was purified by column 
chromatography (CH2Cl2:MeOH, 40:1→20:1) to give 8a (102 mg, 0.22 mmol, 22%) and 9a 
(270 mg, 0.58 mmol, 58%) as white solids. Data for 8a: m.p. 148-150 ºC.  26Dα -36.5 (c 0.54, 
CH2Cl2). IR νmax 3273 (NH), 2990, 1275 (C=S), 1128, 677 cm-1. 1H-NMR (300 MHz, CDCl3, δ 
ppm, J Hz) δ 9.07 (s, 1H, NH), 7.98 (s, 2H, H-arom.), 7.64 (s, 2H, H-arom., NH), 5.17 (brs, 1H, 
H-6), 4.92-4.89 (m, 1H, H-2), 4.58 (d, 1H, J1,2= 6.0, H-1), 3.79-3.73 (m, 1H, H-7a), 3.32 (d, 1H, 
J3,3’ = 11.7, H-3), 3.16-3.06 (m, 2H, H-5, H-5’), 2.85 (dd, 1H, J3’,2 = 4.8, H-3’), 2.13 (dd, 1H, 
J7,7’ = 13.5, J  = 6.9, H-7), 2.01-1.90 (m, 1H, H-7’), 1.53 (s, 3H, -C(CH3)2), 1.35 (s, 3H, -
C(CH3)2). 13C-NMR (75.4 MHz, CDCl3, δ ppm, J Hz) δ 181.0 (C=S), 140.6 (C-arom.), 132.2 (q, 
2JC,F = 33.5, C-arom.), 123.7-123.3 (m, C-arom.), 123.2 (q, 1JC,F = 272.4, CF3), 118.5-118.1 (m, 
C-arom.), 112.1 (-C(CH3)2), 83.3 (C-1), 81.1 (C-2), 70.9 (C-7a), 60.0 (C-5), 59.5 (C-3), 55.9 (C-
6), 34.9 (C-7), 26.4 (-C(CH3)2), 24.4 (-C(CH3)2).  HRMS (ESI-ORBITRAP) m/z: [M+H]+ calcd. 
for C19H22F6N3O2S 470.1331; Found 470.1314. Anal. calcd. for C19H21F6N3O2S: C, 48.61%; H, 
4.51%, N, 8.95%; S, 6.83%, found: C, 48.63%; H, 4.43%; N, 8.97%; S, 6.82%.  Data for 9a: 
 27Dα -25.2 (c 0.50, CH2Cl2). IR νmax 3283 (NH), 2985, 2937, 1275 (C=S), 1125, 681 cm-1. 1H-
NMR (300 MHz, CDCl3, δ ppm, J Hz) δ 8.75 (s, 1H, NH), 7.88 (s, 2H, H-arom.), 7.66 (s, 1H, 
H-arom.), 6.87 (brs, 1H, NH), 4.86-4.83 (m, 2H, H-2, H-6), 4.58 (d, 1H, J = 5.1,    H-1), 3.57-
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3.50 (m, 2H, H-5, H-7a), 3.31 (d, 1H, J3,3’ = 11.7, H-3), 2.89 (dd, 1H, J3’,2 = 4.8,  H-3’), 2.69 (dd, 
1H, J5’,5 = 12.0, J5’,6 = 5.7, H-5’), 2.60-2.51 (m, 1H, H-7), 1.51 (s, 3H, -C(CH3)2), 1.46-1.36 (m, 
1H, H-7’), 1.31 (s, 3H, -C(CH3)2). 13C-NMR (75.4 MHz, CDCl3, δ ppm, J Hz) δ 181.3 (C=S), 
140.2 (C-arom.), 132.3 (q, 2JC,F = 33.6, C-arom.), 123.5-123.1 (m, C-arom.), 123.1 (q, 1JC,F = 
272.4, CF3), 118.8-118.4 (m, C-arom.), 112.3 (-C(CH3)2), 82.7 (C-1), 80.6 (C-2), 71.4 (C-7a), 
59.6 (C-3), 58.8 (C-5), 55.6 (C-6), 33.5 (C-7), 26.3 (-C(CH3)2), 24.2 (-C(CH3)2).  HRMS (ESI-
ORBITRAP) m/z: [M+H]+ calcd for C19H22F6N3O2S 470.1331; Found 470.1316. Anal. calcd. 
for C19H21F6N3O2S: C, 48.61%; H, 4.51%, N, 8.95%; S, 6.83%, found: C, 48.88%; H, 4.55%; N, 
8.54%; S, 6.49%.   
General procedure for acidic deprotection: 
A solution of the corresponding protected compound (0.5 mmol) in HCl (4M):THF (1:1) (12.0 
mL) was stirred at r.t. for 3 h. After evaporation to dryness, the residue was dissolved in THF 
(10 mL) and NH4OH (25%) (5 mL) was added. Evaporation of the solvent and purification 
through silica gel afforded the unprotected derivative. 
N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-[(1S,2R,6R,7aS)-1,2-dihydroxy-pyrrolizidin-6-
yl]thiourea (2a): Acidic deprotection of 8a (52 mg, 0.11 mmol) followed by chromatographic 
purification (CH2Cl2:MeOH:NH4OH, 5:1:0.01), afforded  2a (33 mg, 0.08 mmol, 71%) as a 
white solid.  25Dα  + 9.0 (c 1.1, MeOH). IR νmax 3248 (OH, NH), 1275 (C=S), 1120, 680 cm-1. 
1H-NMR (300 MHz, MeOD, δ ppm, J Hz) δ 8.27 (s, 2H, H-arom.), 7.65 (s, 1H,  H-arom.), 5.08 
(quint, 1H, J6,7 = J6,7’ = J6,5a = J6,5b = 5.7, H-6), 4.38 (q, 1H, J2,1 = J2,3’ = J2,3 = 3.3,  H-2), 4.25-4.15 
(m, 2H, H-1, H-7a), 3.71-3.62 (m, 2H, H-3, H-5), 3.53 (dd, 1H, J5’,5 = 12.0, H-5’), 3.33-3.28 (m, 
1H, H-3’), 2.43-2.39 (m, 2H, H-7). 13C-NMR (75.4 MHz, MeOD, δ ppm, J Hz) δ 183.4 (C=S), 
142.9 (C-arom.), 132.7 (q, 2JC,F = 33.2, C-arom.), 124.7 (q, 1JC,F = 271.4, CF3), 123.8-123.7 (m, 
C-arom.), 118.3-118.0 (m, C-arom.), 77.4 (C-1), 72.8 (C-2), 70.3 (C-7a), 60.0 (C-3), 59.3 (C-5), 
55.5 (C-6), 34.2 (C-7). HRMS (ESI-ORBITRAP) m/z: [M+H]+ calcd. for C16H18F6N3O2S 
430.1018; Found 430.1011. 
N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-[(1S,2R,6S,7aS)-1,2-dihydroxy-pyrrolizidin-6-
yl]thiourea (3a): Acidic deprotection of 9a (52 mg, 0.11 mmol) followed by chromatographic 
purification (CH2Cl2:MeOH:NH4OH, 5:1:0.01), afforded  3a (47 mg, 0.11 mmol, cuant.) as a 
white solid.  24Dα  -38.6 (c 0.75, MeOH). IR νmax 3133 (OH, NH), 1275 (C=S), 1121, 681 cm-1.          
1H-NMR (300 MHz, MeOD, δ ppm, J Hz) δ 8.29 (s, 2H, H-arom.), 7.65 (s, 1H, H-arom.), 5.14-
5.04 (m, 1H, H-6), 4.74 (q, 1H, J2,1 = J2,3’ = J2,3 = 3.6,  H-2),  4.36 (dd, 1H, J1,7a = 6.0, H-1), 4.14-
4.06 (m, 2H, H-7a, H-5), 3.67 (dd, 1H, J3,3’ = 12.3, H-3), 3.46 (dd, 1H, H-3’), 3.20 (dd, 1H, J5’,5 
= 11.7, J5’,6 = 8.7, H-5’), 2.82-2.73 (m, 1H, H-7), 2.21-2.10 (m, 1H, H-7’). 13C-NMR (75.4 
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MHz, MeOD, δ ppm, J Hz) δ 183.5 (C=S), 143.0 (C-arom.), 132.7 (q, 2JC,F = 33.3, C-arom.), 
124.7 (q, 1JC,F = 273.2, CF3), 122.4-122.1 (m, C-arom.), 118.0-117.8 (m, C-arom.), 77.3 (C-1), 
73.3 (C-2), 70.4 (C-7a), 60.1 (C-3), 58.0 (C-5), 55.7 (C-6), 33.9 (C-7). HRMS (ESI-
ORBITRAP) m/z: [M+H]+ calcd. for C16H18F6N3O2S 430.1018; Found 430.1016. 
N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-[(1S,2R,6R,7aS)-1,2-O-isopropylidendioxy-
pyrrolizidin-6-yl]urea (7A8A) and N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-
[(1S,2R,6S,7aS)-1,2-O-isopropylidendioxy-pyrrolizidin-6-yl]urea (9A): To a solution of 
diastereomeric amines 1 (49 mg, 0.25 mmol) in CH2Cl2 (2.5 mL), 3,5-
bis(trifluoromethyl)phenylisoocyanate ((48 µL, 0.27 mmol) was added and the mixture stirred 
for 1 h at 0 ºC. After evaporation to dryness, the crude was purified by chromatography column 
(CH2Cl2:MeOH, 30:1→20:1) to give 8A (28 mg, 0.06 mmol, 24%) and 9A (71 mg, 0.16 mmol, 
63%) as white solids. Data for 8A:  23Dα -37.5 (c 1.1, CH2Cl2). IR νmax 3316 (NH), 2927, 2862, 
1692 (C=O), 1124, 704 cm-1. 1H-NMR (300 MHz, CDCl3, δ ppm, J Hz) δ 8.32 (s, 1H, NH), 
7.94 (s, 2H, H-arom.), 7.43 (s, 1H, H-arom.), 6.91 (d, 1H, JNH,6 = 7.8, NH), 4.97 (dd, 1H, J2,1 = 
6.0, J2,3’ = 4.5, H-2), 4.79-4.74 (m, 1H, H-6), 4.66 (d, 1H, H-1), 3.69 (m, 1H, J7a,7’ = 11.7, J7a,7’ = 
6.3, H-7a), 3.42 (d, 1H, J3,3’ = 12.3, H-3), 3.08 (dd, 1H, J5,5’ = 12.9, J5,6 = 6.6, H-5), 2.97 (dd, 1H, 
J5’,6 = 2.1, H-5’), 2.76 (dd, 1H, H-3’), 1.87 (dd, 1H, J7,7’ = 13.5, J7,7a = 6.6, H-7), 1.75 (td, 1H, 
J7’,6 = 6.3,  H-7’), 1.53, 1.38 (2s, 3H each, -C(CH3)2). 13C-NMR (75.4 MHz, CDCl3, δ ppm, J 
Hz) δ 154.7 (C=O), 141.5 (C-arom.), 132.2 (q, 2JC,F = 33.0, C-arom.), 123.5 (q, 1JC,F = 272.3, 
CF3), 118.2-118.0 (m, C-arom.), 115.4-115.3 (m, C-arom.), 111.8 (-C(CH3)2), 82.5 (C-1), 81.4 
(C-2), 71.2 (C-7a), 60.6 (C-5), 60.3 (C-3), 51.4 (C-6), 35.6 (C-7), 26.1 (-C(CH3)2), 24.2 (-
C(CH3)2).  HRMS (ESI-ORBITRAP) m/z: [M+H]+ calcd. for C19H22F6N3O3 454.1560; Found 
454.1560. Data for 9A:  23Dα -22.1 (c 1.0, CH2Cl2). IR νmax 3313 (NH), 2982, 2932, 1698 
(C=O), 1123, 681 cm-1. 1H-NMR (300 MHz, CDCl3, δ ppm, J Hz) δ 8.64 (s, 1H, NH), 7.79 (s, 
2H, H-arom.), 7.38 (s, 1H, H-arom.), 6.68 (d, 1H, JNH,6 = 6.0, NH), 4.89-4.85 (m, 1H, H-2), 4.60 
(d, 1H, J1,2 = 5.7, H-1), 4.33-4.21 (m, 1H, H-6),  3.52 (dd, 1H, J  = 11.4, J  = 6.9, H-7a), 3.41-
3.32 (m, 2H, H-3, H-5), 3.05 (dd, 1H, J3’,3 = 12.0, J3’,2 = 4.5,  H-3’), 2.66 (dd, 1H, J5’,5 = 12.0, 
J5’,6 = 6.6, H-5’), 2.38-2.29 (m, 1H, H-7), 1.63-1.53 (m, 1H, H-7’), 1.49, 1.31 (2s, 3H each, -
C(CH3)2). 13C-NMR (75.4 MHz, CDCl3, δ ppm, J Hz) δ 155.4 (C=O), 140.9 (C-arom.), 132.2 
(q, 2JC,F = 33.1, C-arom.), 123.3 (q, 1JC,F = 272.4, CF3), 118.4-117.9 (m, C-arom.), 115.8-115.5 
(m, C-arom.), 111.9 (-C(CH3)2), 83.2 (C-1), 80.9 (C-2), 71.0 (C-7a), 59.8 (C-5), 59.1 (C-3), 52.4 
(C-6), 34.2 (C-7), 26.4 (-C(CH3)2), 24.4 (-C(CH3)2). HRMS (ESI-ORBITRAP) m/z: [M+H]+ 
calcd. for C19H22F6N3O3 454.1560; Found 454.1560. 
N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-[(1S,2R,6R,7aS)-1,2-dihydroxy-pyrrolizidin-6-
yl]urea (2A): Acidic deprotection of 8A (32 mg, 0.07 mmol) followed by chromatographic 
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purification (CH2Cl2:MeOH:NH4OH, 5:1:0.2), afforded 2A (25 mg, 0.06 mmol, 85%) as a white 
solid.  26Dα -15.6 (c 0.78, MeOH). IR νmax 3303 (OH, NH), 2937, 1675 (C=O), 1274, 1119, 681  
cm-1. 1H-NMR (300 MHz, MeOD, δ ppm, J Hz) δ 8.00 (s, 2H, H-arom.), 7.48 (s, 1H, H-arom.), 
4.32 (quint, 1H, J6,7 = J6,7’ = J6,5 = J6,5’ = 5.7, H-6), 4.24-4.20 (m, 1H, H-2), 3.86 (dd, 1H, J1,7a = 
6.3, H-1), 3.60-3.54 (m, 1H, H-7a), 3.19 (dd, 1H, J3,3’ = 11.4, H-3), 2.91-2.89 (m, 2H, H-5), 2.85 
(dd, 1H, H-3’), 2.11-1.99 (m, 2H, H-7). 13C-NMR (75.4 MHz, MeOD, δ ppm, J Hz) δ 157.0 
(C=O), 143.3 (C-arom.), 133.1 (q, 2JC,F = 32.9, C-arom.), 124.8 (q, 1JC,F = 271.5, CF3), 119.4-
118.9 (m, C-arom.), 115.7-115.4 (m, C-arom.), 78.8-78.6 (m, C-1), 73.7-73.6 (m, C-2), 68.2-
68.0 (m, C-7a), 61.2 (C-5), 60.4 (C-3), 51.9-51.8 (m, C-6), 36.8 (C-7). HRMS (ESI-
ORBITRAP) m/z: [M+H]+ calcd. for C16H18F6N3O3 414.1247; Found 414.1242. 
N-[(3,5-Bis(trifluoromethyl)phenyl)]-N’-[(1S,2R,6S,7aS)-1,2-dihydroxy-pyrrolizidin-6-
yl]urea (3A): Acidic deprotection of 9A (38 mg, 0.08 mmol) followed by chromatographic 
purification (CH2Cl2:MeOH:NH4OH, 4:1:0.2), afforded 3A (24 mg, 0.06 mmol, 70%) as a white 
solid.  26Dα  -25.4 (c 0.77, MeOH). IR νmax 3290 (OH, NH), 2924, 1674 (C=O), 1276, 1121, 681 
cm-1. 1H-NMR  (300 MHz, MeOD, δ ppm, J Hz) δ 8.00 (s, 2H, H-arom.), 7.48 (s, 1H,  H-
arom.), 4.35-4.26 (m, 2H, H-6, H-2), 3.95 (dd, 1H, J = 5.7, J = 4.5, H-1), 3.57-3.49 (m, 1H, H-
7a), 3.38 (dd, 1H, J5,5’ = 9.3, J5,6 = 6.3, H-5), 3.15 (dd, 1H, J3,3’ = 11.4, J3,2 = 4.2, H-3), 2.91 (dd, 
1H, J3’,2 = 4.8, H-3’), 2.53-2.44 (m, 2H, H-7, H-5’), 1.67-1.61 (m, 1H, H-7’). 13C-NMR (75.4 
MHz, MeOD, δ ppm, J Hz) δ 156.9 (C=O), 143.2 (C-arom.), 133.1 (q, 2JC,F =33.0, C-arom.), 
124.8 (q, 1JC,F =271.4, CF3), 119.4-119.1 (m, C-arom.), 115.7-115.6 (m, C-arom.), 78.9 (C-1), 
73.8 (C-2), 68.5 (C-7a), 60.7 (C-5), 59.9 (C-3), 52.8 (C-6), 36.9 (C-7). HRMS (ESI-
ORBITRAP) m/z: [M+H]+ calcd. for C16H18F6N3O3 414.1247; Found 414.1241. 
(1S,2R,6R,7aS)-1,2-O-Isopropylidendioxy-6-[(4-(3,5-bis(trifluoromethyl)phenyl))-1H-1,2,3-
triazole-1-yl)]pyrrolizidine (11) and (1S,2R,6S,7aS)-1,2-O-isopropylidendioxy-6-[(4-(3,5-
bis(trifluoromethyl)phenyl))-1H-1,2,3-triazole-1-yl)]pyrrolidizidine (12): To a solution of 
diastereomeric amines 1 (100 mg, 0.50 mmol) in MeOH:H2O (2:1) (2.1 mL), NaHCO3 (189 mg, 
2.00 mmol), CuSO4·5H2O (13 mg, 0.05 mmol) and a solution of NfN323 (326 mg, 1.00 mmol) in 
Et2O (1.4 mL) were added. After stirring at r.t for 6 h, 1-ethynyl-3,5-
bis(trifluoromethyl)benzene (120 µL, 0.55 mmol) and sodium ascorbate (150 mg, 0.75 mmol) 
were added and the mixture was stirred at r.t. overnight. Then, solvent was evaporated and the 
residue dissolved in CH2Cl2 and washed with sat. aq. soln. of NaHCO3. The organic phase was 
dried (Na2SO4), filtered and evaporated and the crude product was purified through 
chromatography column on silica gel (Et2O:acetone, 15:1→ 6:1) to give 11 (41 mg, 0.09 mmol, 
18%) and 12 (115 mg, 0.25 mmol, 50%) as yellowish oils. Data for 11:  25Dα -14.6 (c 0.87, 
CH2Cl2). IR νmax 2927, 1277, 1126, 682 cm-1. 1H-NMR (300 MHz, CDCl3, δ ppm, J Hz) δ 8.28 
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(s, 2H, H-arom.), 8.11 (s, 1H,  H-5(triazole)), 7.82 (s, 1H, H-arom.), 5.47-5.40 (m, 1H, H-6), 
4.92 (td, 1H, J2,3’ = 6.0, J = 2.1, H-2), 4.60 (dd, 1H, J = 6.0, J = 1.8, H-1), 3.92-3.86 (m, 1H, H-
7a), 3.42-3.37 (m, 3H, H-5, H-5’, H-3), 2.92 (dd, 1H, J3,3’ = 12.0, H-3’), 2.46 (ddd, 1H, J7,7’ = 
14.4, J = 7.5, J  = 2.4, H-7), 2.30-2.19 (m, 1H, H-7’), 1.56, 1.35 (2s, 3H each, -C(CH3)2). 13C-
NMR (75.4 MHz, CDCl3, δ ppm, J Hz) δ 145.7 (C-4(triazole)), 133.0 (C-arom.), 132.5 (q,  2JC,F 
= 33.4, C-arom.), 126.0-125.7 (m, C-arom.), 123.5 (q, 1JC,F=  272.4, CF3), 121.9-121.7 (m, C-
arom.), 119.5 (C-5(triazole)), 112.6 (-C(CH3)2), 84.8 (C-1), 81.4 (C-2), 70.5 (C-7a), 61.4 (C-6), 
60.5 (C-5), 59.2 (C-3), 36.2 (C-7), 27.1 (-C(CH3)2), 25.1 (-C(CH3)2).  HRMS (ESI-ORBITRAP) 
m/z: [M+H]+ calcd. for C20H21F6N4O2 463.1563; Found 463.1559. Data for 12:  25Dα -37.5 (c 
0.57, CH2Cl2). IR νmax 2925, 1277, 1127, 682 cm-1. 1H-NMR (300 MHz, CDCl3, δ ppm, J Hz) δ 
8.26 (s, 2H, H-arom.), 7.94 (s, 1H, H-5(triazole)), 7.83 (s, 1H, H-arom.), 5.19-5.09 (m, 1H, H-
6), 4.94-4.91 (m, 1H, H-2), 4.69 (brd, 1H, J = 6, H-1), 3.76-3.69 (m, 2H, H-5, H-7a), 3.40-3.21 
(m, 3H, H-5’, H-3, H-3’), 2.70-2.61 (m, 1H, H-7), 2.36-2.25 (m, 1H, H-7’), 1.56, 1.34 (2s, 3H 
each, -C(CH3)2). 13C-NMR (75.4 MHz, CDCl3, δ ppm, J Hz) δ 145.4 (C-4(triazole)), 132.7 (C-
arom.), 132.5 (q,  2JC,F = 33.6, C-arom.), 125.9-125.6 (m, C-arom.), 123.5 (q, 1JC,F = 272.5, CF3), 
122.0-121.7 (m, C-arom.), 120.9-120.7 (C-5(triazole)), 112.0 (-C(CH3)2), 83.7 (C-1), 81.3 (C-
2), 70.4 (C-7a), 62.6 (C-6), 59.2 (C-5), 59.1 (C-3), 35.3 (C-7), 26.8 (-C(CH3)2), 24.9 (-C(CH3)2).  
HRMS (ESI-ORBITRAP) m/z: [M+H]+ calcd. for C20H21F6N4O2 463.1563; Found 463.1574. 
(1S,2R,6R,7aS)-1,2-Dihydroxy-6-[(4-(3,5-bis(trifluoromethyl)phenyl))-1H-1,2,3-triazole-1-
yl)]pyrrolizidine (4): Acidic deprotection of 11 (28.3 mg, 0.06 mmol) followed by 
chromatographic purification (CH2Cl2:MeOH:NH4OH, 8:1:0.01), afforded  4 (16.3 mg, 0.04 
mmol, 63%)  as a white solid.  26Dα  -0.5 (c 1.17, MeOH). IR νmax 3324 (OH), 2935, 2851, 
1277, 1123, 702 cm-1. 1H-NMR (300 MHz, MeOD, δ ppm, J Hz) δ 8.74 (s, 1H, H-5(triazole)), 
8.44 (s, 2H, H-arom.), 7.93 (s, 1H, H-arom.), 5.42-5.35 (m, 1H, H-6), 4.32-4.27 (m, 1H, H-2), 
3.96 (dd, 1H, J1,7a = 6.9, H-1), 3.74 (q, 1H, J7a,7 = J7a,7’ = 6.9, H-7a), 3.44 (dd, 1H, J5,5’ = 11.7, J5,6 
= 4.2, H-5), 3.27-3.19 (m, 2H, H-3, H-5’), 2.92 (dd, 1H, J3’,3 = 11.7, H-3’), 2.69-2.60 (m, 1H, H-
7), 2.43-2.34 (m, 1H, H-7’). 13C-NMR (75.4 MHz, MeOD, δ ppm, J Hz) δ 146.0 (C-4(triazole)), 
134.7 (C-arom.), 133.5 (q, 2JC,F = 33.4, C-arom.), 126.7-126.6 (m, C-arom.), 124.8 (q, 1JC,F = 
271.7, CF3), 122.8 (C-5(triazole)), 122.4-122.3 (m, C-arom.), 78.8 (C-1), 74.2 (C-2), 68.5 (C-
7a),  63.1 (C-6), 61.2 (C-5), 60.3 (C-3), 36.8 (C-7). HRMS (ESI-ORBITRAP) m/z: [M+H]+ 
calcd. for C17H17F6N4O2 423.1250; Found 423.1244. 
(1S,2R,6S,7aS)-1,2-Dihydroxy-6-[(4-(3,5-bis(trifluoromethyl)phenyl))-1H-1,2,3-triazole-1-
yl)]pyrrolidizidine (5): Acidic deprotection of 12 (83 mg, 0.18 mmol) followed by 
chromatographic purification (CH2Cl2:MeOH:NH4OH, 5:1:0.02), afforded  5 (65 mg, 0.16 
mmol, 86%)  as a white solid.  26Dα  -25.6 (c 0.98, MeOH). IR νmax 3319 (OH), 2925, 1277, 
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1121, 682 cm-1. 1H-NMR (300 MHz, MeOD, δ ppm, J Hz) δ 8.77 (s, 1H, H-5(triazole)), 8.44 (s, 
2H, H-arom.), 7.94 (s, 1H,     H-arom.), 5.31-5.21 (m, 1H, H-6), 4.34 (q, 1H, J2,1 = J2,3 = J2,3’ = 
4.2, H-2), 4.05 (dd, 1H, J1,7a = 5.7, H-1), 3.75-3.67 (m, 2H, H-5, H-7a), 3.25-3.20 (m, 2H, H-3’, 
H-5’), 3.05 (dd, 1H, J3,3’ = 11.4, H-3), 2.88-2.79 (m, 1H, H-7), 2.43-2.32 (m, 1H, H-7’). 13C-
NMR (75.4 MHz, MeOD, δ ppm, J Hz) δ 146.0 (C-4(triazole)), 134.5 (C-arom.), 133.7 (q, 2JC,F 
= 33.4, C-arom.), 126.8-126.6 (m, C-arom.), 124.7 (q, 1JC,F = 271.6, CF3), 123.4 (C-5(triazole)), 
122.6-122.3 (m, C-arom.), 78.6 (C-1), 74.0 (C-2), 68.7 (C-7a), 62.4 (C-6), 60.3 (C-5), 60.0 (C-
3), 36.8 (C-7).  HRMS (ESI-ORBITRAP) m/z: [M+H]+ calcd. for C17H17F6N4O2 423.1250; 
Found 423.1239. 
(1S,2R,6S,7aS)-6-Amino-1,2-O-dihydroxy-pyrrolizidine (16): Boc2O (509 mg, 2.33 mmol) 
was added to a solution of amines 1 (272.6 mg, 1.37 mmol) in MeOH (6 mL) and the mixture 
was stirred at r.t. for 8 h. Evaporation of the solvent and chromatographic purification on silica 
gel (CH2Cl2:MeOH, 30:1) afforded 14 (199 mg, 0.67 mmol, 49%) and 15 (76 mg, 0.25 mmol, 
18%) as white solids. Compound 14 (90.9 mg, 0.3 mmol) was dissolved in THF (1.5 mL) and 
4M HCl (1.5 mL) was added. The solution was stirred at r.t. for 6 h. Evaporation of the solvent 
and chromatographic purification on Dowex 50WX8 eluting with MeOH, H2O and NH4OH 
25%, afforded 16 (47.1 mg, 0.29 mmol, 99%)  as a brown solid.  26Dα  -21.1 (c 0.74, MeOH). 
1H-NMR (300MHz, MeOD, δ ppm, J Hz) δ 4.28 ( ap q, 1H, J2,3b= 5.1, J2,3a= 4.8, J2,1= 4.5, H-2), 
3.90 (ap t, 1H, J1,7a= 5.1, H-1), 3.51-3.39 (m, 2H, H-6, H-7a), 3.21 (dd, 1H, J5a,6= 6.0, J5a,5b= 9.0, 
H-5a), 3.08 (dd, 1H, J3a,3b= 11.4, H-3a), 2.86 (dd, 1H, H-3b), 2.38-2.30 (m, 1H, H-7), 2.28 (t, 
1H, J5b,6= 9.5, H-5b), 1.45-1.35 (m, 1H, H-7’). 13C-NMR (75.4 MHz, MeOD, δ ppm, J Hz) 78.9 
(C-1), 73.6 (C-2), 69.1 (C-6), 63.7 (C-5), 59.6 (C-3), 54.4 (C-7a), 39.8 (C-7). HRMS (ESI-
ORBITRAP) m/z: [M+H]+ calcd. for C7H15N2O2 159.1128; Found 159.1123.      
N-(2-Naphthyl)-N’-[(1S,2R,6S,7aS)-1,2-dihydroxy-pyrrolizidin-6-yl]thiourea (3i): To a 
solution of amine 16 (41 mg, 0.26 mmol) in MeOH (2.0 mL), 2-naphthyl isocyanate (55.6 mg, 
0.3 mmol) was added and the mixture stirred for 5 h at r.t. After evaporation to dryness, the 
crude was purified by chromatography column (CH2Cl2:MeOH, 1:1) to give 3i (51 mg, 0.15 
mmol, 57%) as a white solid.  26Dα  -16.8 (c 0.67, CDCl3:MeOH 1:1). 1H-NMR (300MHz, 
MeOD:CDCl3 1:1, δ ppm, J Hz) δ 7.92-7.87 (m, 3H, Arom), 7.56-7.50 (m, 3H, Arom), 7.43 (dd, 
1H, JH,H= 7.5, JH,H= 1.2, Arom)  5.06 (m, 1H, H-6) 4.13 (q, 1H, J2,1= J2,3a= J2,3b = 4.6, H-2), 3.72 
(t. 1H, J1,7a= 4.6, H-1), 3.45-3.35 (m, 2H, H-5a, H-7a), 2.99 (dd, 1H, J3a,3b=11.7, H-3a), 2.69 
(dd, 1H, H-3b) 2.46-2.37 (m, 1H, H-7), 2.25 (t, 1H, J5b,5a= J5b,6= 9.4, H-5b), 1.42 (q, 1H, J7’,7= 
J7’,6= J7’,7a = 10.6, H-7’). 13C-NMR (75.4 MHz, CDCl3:MeOH 1:1, δ ppm) δ 182.4 (C=S), 135.3, 
130.7, 129.0, 128.9, 127.5, 127.2, 126.2, 125.9, 123.1 (Arom), 78.1 (C-1), 72.9 (C-2), 67.7 (C-
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7a), 59.5 (C-5), 59.2 (C-3), 56.7 (C-6), 35.8 (C-7).  HRMS (ESI-ORBITRAP) m/z: [M+H]+ 
calcd. for C18H22N3O2S  344.1427; Found 344.1423. 
X-ray Structural Analysis of compounds 8a and 9a·HCl. 
Crystals of suitable size for X-ray diffraction analysis of 8a and 9a·HCl were coated with dry 
perfluoropolyether and mounted on glass fibres and fixed in a cold nitrogen stream (T = 213 K) 
to the goniometer head. Data collection was performed on a Bruker-Nonius X8Apex-II CCD 
diffractometer, using monochromatic radiation λ(Mo Kα) = 0.71073 Å, by means of ω and φ 
scans with a width of 0.50 degree. The data were reduced (SAINT)28 and corrected for 
absorption effects by the multi-scan method (SADABS).29 The structures were solved by direct 
methods (SIR-2002)30 and refined against all F2 data by full-matrix least-squares techniques 
(SHELXL-2016/6)31 minimizing w[Fo2-Fc2]2. All non-hydrogen atoms were refined 
anisotropically. The hydrogen atoms were included from calculated positions and refined riding 
on their respective carbon atoms with isotropic displacement parameters. One CF3- group of the 
compound 8a was found to be clearly disordered and was modelled in two positions with the 
same occupation coefficient. A search for solvent accessible voids in the crystal structure for 
both compounds using PLATON32, showed a potential solvent volume, impossible to model 
even with the most severe restraints. The corresponding CIF data represent SQUEEZE33 treated 
structures, with the undefined solvent excluded from the structural model. The SQUEEZE 
results were appended to the CIF.  A summary of cell parameters, data collection, structure 
solution, and refinement for these two crystal structures are given bellow. The corresponding 
crystallographic data were deposited with the Cambridge Crystallographic Data Centre as 
supplementary publications. The data can be obtained free of charge via 
www.ccdc.ac.uk/data.request/cif. 
Crystal data for 8a: C19H21F6N3O2S•CH2Cl2, M = 554.37, a = 9.9180(4) Å, b = 9.8167(4) Å, c 
= 12.7446(5) Å, α = 90°, β = 99.023(2)°, γ = 90°, V = 1225.49(9) Å3, T = 193(2) K, space group 
P21, Z = 2, 18120 reflections measured, 4446 independent reflections (Rint = 0.0289). The final 
R1 values were 0.0494 (I > 2σ(I)). The final wR(F2) values were 0.1448 (I > 2σ(I)). The final R1 
values were 0.0514 (all data). The final wR(F2) values were 0.1465 (all data). The goodness of 
fit on F2 was 1.047. Flack parameter = 0.04(2). CCDC 1834757. 
Crystal data for 9a.HCl: C19H22F6N3O2S•Cl, M = 505.90, a = 12.9162(4) Å, b = 31.0699(10) 
Å, c = 5.8565(2) Å, α = 90°, β = 90°, γ = 90°, V = 2350.24(13) Å3, T = 193(2) K, space group 
P21212, Z = 4, 26691 reflections measured, 4121 independent reflections (Rint = 0.0363). The 
final R1 values were 0.0554 (I > 2σ(I)). The final wR(F2) values were 0.1344 (I > 2σ(I)). The 
final R1 values were 0.0599 (all data). The final wR(F2) values were 0.1369 (all data). The 
goodness of fit on F2 was 1.150. Flack parameter = -0.03(2).  CCDC 1834758. 
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 Supporting information 
1H- and 13C-NMR spectra for all the new compounds. NOESY spectra for 2A and 4. Analysis of 
the library by ESI-MS spectra. Lineweaver-Burk plots and secondary representations for 
inhibitor 3i. X-ray crystallography data for 8a and 9a. 
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